One pill may tame both itchy skin and stubborn liver disease

NCT ID NCT07678645

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests whether upadacitinib, a drug already approved for eczema, can help people who have both atopic dermatitis (a type of eczema) with moderate to severe itching and a hard-to-treat autoimmune liver disease called cholangitis. The drug works by blocking a pathway involved in both itching and liver inflammation. Researchers will measure changes in itch severity, liver enzyme levels, and liver stiffness over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
upadacitinib
What this could lead to
If it works, this could offer a new treatment option for people with both atopic dermatitis and hard-to-treat autoimmune liver disease, potentially easing itching and slowing liver damage.
What could go wrong
This is a small, early-phase study with no placebo group, so results may not be conclusive. Upadacitinib can have side effects like infections or blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • RenJi Hospital

    Shanghai, Shanghai Municipality, 200001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.